As SGYP and PGNX both await potential FDA approvals this year, BTIG’s Tim Chiang shares his positive two cents on these drug makers he believes present meaningful upside potential.
Commercial Revenues Are Likely in 2018 Despite Modest Delay in Filing
In a research report published Tuesday, Brean Capital analyst Jason Wittes assumed coverage on shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), with a Buy rating and price …
Shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) jumped nearly 27% Wednesday following the news of FDA approval of opioid-induced constipation (OIC)-fighting drug Oral Relister, invented to help …
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced results of operations for the second quarter and six months ended June 30, 2015.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced that it has entered into an exclusive worldwide licensing agreement with Johns Hopkins University for [18F]DCFPyL (“PyL”), a clinical-stage …
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative ways to target and treat cancer, announced today that the U.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced details of its planned Phase 3 clinical trial for 1404, a developmental stage small molecule designed to help visualize …
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that Valeant submitted a New Drug Application to the U.
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc.
